ReviewEuropean journal of heart failure2022
Drug therapy for heart failure with reduced ejection fraction: what is the 'right' dose?
Review in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning to optimize use of natriuretic peptides in the diagnosis of acute heart failure.European heart journal. Acute cardiovascular care · 2025Pooled it
- A STRONG call for intensive oral heart failure therapy in acute heart failure patients.Heart failure reviews · 2025Review
- Quantifying Hemodynamic Cardiac Stress and Cardiomyocyte Injury in Normotensive and Hypertensive Acute Heart Failure.Biomedicines · 2024Article
- How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review.Journal of clinical medicine · 2024Article
- Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction.BMC cardiovascular disorders · 2024Article
- Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction.Drugs · 2023Review
- 2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure.Acta Cardiologica Sinica · 2023Article
- Treatment Strategies of Improving Quality of Care in Patients With Heart Failure.Korean circulation journal · 2023Review
- Phenotypic patient profiling for improved implementation of guideline-directed medical therapy: An exploratory analysis in a large real-world chronic heart failure cohort.Frontiers in pharmacology · 2023Article
- Insights into foundational therapies for heart failure with reduced ejection fraction.Clinical cardiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
New guidelines have emphasized the primacy of starting the four key life-saving therapies for patients with heart failure and reduced ejection fraction as quickly as possible, with titration to 'target dose' of these, as secondary consideration. In this article, we examine the reasons for this change in emphasis and revisit the evidence regarding the dosing of pharmacological therapy in heart failure. We demonstrate the early benefits obtained with even low doses of most of the foundational therapies for heart failure and reduced ejection fraction. We also clarify that the 'target dose' of those therapies requiring titration was a goal based on tolerability and often not reached in trials, i.e. the proven benefits of our foundational therapies were demonstrated with an average dose that was less than target and many patients in these trials were treated with sub-target doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.